MA52778A - Méthodes de traitement de troubles associés au récepteur s1p1 - Google Patents

Méthodes de traitement de troubles associés au récepteur s1p1

Info

Publication number
MA52778A
MA52778A MA052778A MA52778A MA52778A MA 52778 A MA52778 A MA 52778A MA 052778 A MA052778 A MA 052778A MA 52778 A MA52778 A MA 52778A MA 52778 A MA52778 A MA 52778A
Authority
MA
Morocco
Prior art keywords
receptor
treatment
methods
disorders associated
disorders
Prior art date
Application number
MA052778A
Other languages
English (en)
Inventor
Ronald J Christopher
Abu J M Sadeque
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67253955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA52778(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MA52778A publication Critical patent/MA52778A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
MA052778A 2018-06-06 2019-06-05 Méthodes de traitement de troubles associés au récepteur s1p1 MA52778A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862681426P 2018-06-06 2018-06-06
US201862746946P 2018-10-17 2018-10-17
US201962850470P 2019-05-20 2019-05-20

Publications (1)

Publication Number Publication Date
MA52778A true MA52778A (fr) 2021-04-21

Family

ID=67253955

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052778A MA52778A (fr) 2018-06-06 2019-06-05 Méthodes de traitement de troubles associés au récepteur s1p1

Country Status (13)

Country Link
US (2) US12156866B2 (fr)
EP (1) EP3801459B1 (fr)
JP (1) JP7397011B2 (fr)
KR (1) KR102859841B1 (fr)
CN (1) CN112601516A (fr)
AU (1) AU2019280822A1 (fr)
BR (1) BR112020024762A2 (fr)
CA (1) CA3102136A1 (fr)
ES (1) ES2987794T3 (fr)
IL (1) IL279180A (fr)
MA (1) MA52778A (fr)
MX (1) MX2020013157A (fr)
WO (1) WO2019236757A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2786994C (fr) 2010-01-27 2018-01-16 Arena Pharmaceuticals, Inc. Procedes de preparation d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta]indol-3-yl) acetique et de ses sels
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
JP2020507610A (ja) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ， インコーポレイテッド 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法
WO2020072824A1 (fr) * 2018-10-03 2020-04-09 Arena Pharmaceuticals, Inc. Méthodes pour le traitement des troubles de la sclérodermie
WO2021163355A1 (fr) * 2020-02-11 2021-08-19 Arena Pharmaceuticals, Inc. Formulations et méthodes de traitement d'affections liées au récepteur s1p1
US20250152556A1 (en) * 2022-01-13 2025-05-15 Arena Pharmaceuticals, Inc. Etrasimod for use in treating s1p1 receptor-associated disorders in combination with hormone treatment

Family Cites Families (520)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH389134A (de) 1960-03-15 1965-03-15 Ciba Geigy Verfahren zur Herstellung neuer Anthrachinonküpenfarbstoffe
NL293572A (fr) 1962-06-07
CH478819A (de) 1965-10-22 1969-09-30 Ciba Geigy Verfahren zur Herstellung neuer N,N'-Di-(pyrimidyl-(4)-aminoalkyl)-diazacycloalkanen
CH480410A (de) 1967-01-09 1969-10-31 Geigy Ag J R Verfahren zur Herstellung von wasserlöslichen Azopyrimidinfarbstoffen
CA961052A (en) 1967-01-12 1975-01-14 Max Schellenbaum N-2-ethylhexyl-n'-aryl ureas and preparation containing them
FR1593586A (fr) 1967-10-17 1970-06-01
US3608087A (en) 1968-06-21 1971-09-21 Merck & Co Inc Feed compositions
US3887329A (en) 1969-05-05 1975-06-03 Ciba Geigy Ag Hexamethyl phosphotriamide-dye compositions
BE756953A (fr) 1969-10-02 1971-04-01 Merck & Co Inc Potentialisation d'antibiotiques
US3686238A (en) 1970-01-19 1972-08-22 Syntex Corp Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US3852434A (en) 1970-09-11 1974-12-03 Merck & Co Inc Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof
US3966744A (en) 1971-01-11 1976-06-29 Syva Company Spin labeled compounds
US3690834A (en) 1971-01-11 1972-09-12 Syva Co Ligand determination with spin labeled compounds by receptor displacement
DE2106585A1 (de) 1971-02-11 1972-08-24 Farbenfabriken Bayer Ag, 5090 Leverkusen Aminothiodiazole und Thiodiazol-Azofarbstoffe
CH560197A5 (en) 1971-05-17 1975-03-27 Ciba Geigy Ag 2-alkylthio-4,6-bis (subst amino)-5-nitropyrimidines - - herbicides
CH558137A (de) 1971-05-17 1975-01-31 Ciba Geigy Ag Mittel zur beeinflussung des pflanzenwachstums.
DE2226703A1 (de) 1972-05-25 1973-12-13 Schering Ag Neue tetrahydrocarbazolderivate und verfahren zu ihrer herstellung
US3966764A (en) 1972-07-10 1976-06-29 Syva Company Ligand determination of spin labeled compounds by receptor displacement-amphetamine analogs
US3849420A (en) 1972-10-20 1974-11-19 Dow Chemical Co Bis-(alkylthio-and alkylsulfonyl)-pentachloroquinolines
CH574206A5 (fr) 1972-11-16 1976-04-15 Ciba Geigy Ag
DE2340569C2 (de) 1973-08-10 1982-12-02 Bayer Ag, 5090 Leverkusen Azofarbstoffe
AT340933B (de) 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
US4057559A (en) 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4101541A (en) 1973-12-21 1978-07-18 Ciba-Geigy Corporation 3-Cyano-1,2,4-thiadiazolyl-5-czo dyestuffs
CH584739A5 (fr) 1973-12-21 1977-02-15 Ciba Geigy Ag
FR2258841B1 (fr) 1974-01-29 1977-11-04 Ugine Kuhlmann
AT327605B (de) 1974-05-06 1976-02-10 Ciba Geigy Ag Mittel zur hemmung des pflanzenwachstums
AU492126B2 (en) 1974-05-14 1975-11-20 Ciba-Geigy Ag Nitropyrimidine derivatives
FR2306697A1 (fr) 1975-04-10 1976-11-05 Sogeras Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants
US4139705A (en) 1977-05-20 1979-02-13 The Dow Chemical Company Pyrazolopyrimidines
US4189579A (en) 1977-05-20 1980-02-19 The Dow Chemical Company Aminoalkylthiopurines
DE2731264A1 (de) 1977-07-11 1979-02-01 Boehringer Mannheim Gmbh Neue 1-acyl-2-cyanaziridine, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zubereitungen
JPS6038696B2 (ja) 1977-12-09 1985-09-02 コニカ株式会社 ハロゲン化銀カラ−写真感光材料
US4242507A (en) 1978-02-23 1980-12-30 Fujisawa Pharmaceutical Co., Ltd. Sulfonic acid esters
DE2831580C2 (de) 1978-07-18 1980-09-18 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Reagens zur Bestimmung von Glycerin
DE2831850A1 (de) 1978-07-20 1980-02-07 Basf Ag N-arylsulfonylpyrrole, ihre herstellung und diese enthaltende therapeutische mittel
DE2906603A1 (de) 1979-02-21 1980-09-04 Boehringer Mannheim Gmbh N-substituierte aziridin-2-carbonsaeurederivate, verfahren zu deren herstellung sowie diese substanzen enthaltende arzneimittel
US4343804A (en) 1979-03-26 1982-08-10 A. H. Robins Company, Inc. 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
WO1981003174A1 (fr) 1980-04-28 1981-11-12 Teijin Ltd Derives de thiazolo (3,2-a) pyrimidine, leur procede de preparation, et medicaments les contenant
EP0053678A1 (fr) 1980-12-05 1982-06-16 BASF Aktiengesellschaft Amino-5-phényl-1-cyano-4-pyrazoles, herbicides les contenant, leur procédé de préparation et leur application comme herbicides
RU938559C (ru) 1980-12-12 1993-11-30 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе S-Производные 5-амино-6-меркаптопиримидина, обладающие противоопухолевым и цитостатическим действием
DOP1981004033A (es) 1980-12-23 1990-12-29 Ciba Geigy Ag Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
US4476248A (en) 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen
DE3334455A1 (de) 1983-03-04 1984-09-06 Bayer Ag, 5090 Leverkusen Guanidin - derivate
US4612376A (en) 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
ZA848275B (en) 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
DE3406329A1 (de) 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
JPS6157587A (ja) 1984-08-29 1986-03-24 Shionogi & Co Ltd 縮合複素環誘導体および抗潰瘍剤
PH22302A (en) 1985-02-11 1988-07-22 Fujisawa Pharmaceutical Co Piperidine compounds
ZA861446B (en) 1985-03-01 1986-10-29 Duphar Int Res Benzoyl urea derivatives having anti-tumor activity
DE3601196A1 (de) 1986-01-17 1987-07-23 Merck Patent Gmbh 1,4-dihydropyridine
US4810699A (en) 1987-02-20 1989-03-07 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them
CA1340284C (fr) 1987-03-19 1998-12-22 Zeneca Inc. Diones cycliques avec substitution, herbicides
EP0324426B1 (fr) 1988-01-11 1996-06-19 Fuji Photo Film Co., Ltd. Procédé pour former des images négatives à très haut contraste
US4782076A (en) 1988-03-01 1988-11-01 American Home Products Corporation Substituted 2,3,4,9-tetrahydro-1H-carbazole-1-acetic acid derivatives, composition and use
PT95692A (pt) 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
NZ238863A (en) 1990-07-19 1993-03-26 Janssen Pharmaceutica Nv Substituted thiazolyl and pyridinyl derivatives
US5221678A (en) 1990-07-26 1993-06-22 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
WO1992012976A1 (fr) 1991-01-16 1992-08-06 Yoshitomi Pharmaceutical Industries, Ltd. Compose de pyridine utilise comme medicament selectif et nouveau compose de pyridine
CA2070978A1 (fr) 1991-06-11 1992-12-12 William J. Greenlee Inhibiteurs cycliques de la renine
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
JPH0533359A (ja) 1991-08-02 1993-02-09 Kubota Corp 全旋回型の小型バツクホウ
EP0556889A1 (fr) 1992-02-18 1993-08-25 Duphar International Research B.V Méthode pour la préparation de aryl(homo)préparation
DE4208254A1 (de) 1992-03-14 1993-09-16 Hoechst Ag Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
TW237456B (fr) 1992-04-09 1995-01-01 Ciba Geigy
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
NZ314207A (en) 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
DE4241632A1 (de) 1992-12-10 1994-06-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
US5998499A (en) 1994-03-25 1999-12-07 Dentsply G.M.B.H. Liquid crystalline (meth)acrylate compounds, composition and method
JPH0753546A (ja) 1993-08-09 1995-02-28 Kuraray Co Ltd ジアリール置換複素環化合物およびその医薬用途
CA2174080A1 (fr) 1993-10-12 1995-04-20 Paul Edward Aldrich 1n-alkyle-n-arylpyrimidinamines et leurs derives
GB9400889D0 (en) 1994-01-18 1994-03-16 Sandoz Ltd Novel compounds
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
RU2128996C1 (ru) 1994-09-09 1999-04-20 Ниппон Синяку Ко., Лтд. Гетероциклическое производное и лекарственное средство
PT801059E (pt) 1994-11-29 2001-10-30 Dainippon Pharmaceutical Co Derivado indol
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
DE69630214T2 (de) 1995-03-10 2004-07-15 Berlex Laboratories, Inc., Richmond Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1996033994A1 (fr) 1995-04-28 1996-10-31 Nippon Soda Co., Ltd. Derives amino-substitues, leur procede de preparation et herbicide
JPH10506126A (ja) 1995-05-12 1998-06-16 ニューロゲン コーポレイション 新規なデアザプリン誘導体；ｃｒｆ１特異性リガンドの新規なクラス
WO1996036613A1 (fr) 1995-05-19 1996-11-21 Nippon Soda Co., Ltd. Derives d'acides benzoiques substitues, procede de production desdits derives et herbicides
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US6956047B1 (en) 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
KR0169813B1 (ko) 1995-07-12 1999-01-15 김종인 4-아미노-3-아실나프티리딘 유도체
US6248571B1 (en) 1995-08-31 2001-06-19 Lonza Ag Method of producing dihydroxypyrimidine derivatives
US6069176A (en) 1995-10-26 2000-05-30 Mitsubishi-Tokyo Pharmaceuticals, Inc. Phenylethanolamine compounds useful as β 3 agonists, process for producing the same, and intermediates in the production of the same
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
USH2007H1 (en) 1996-01-19 2001-12-04 Fmc Corporation Insecticidal N-heterocyclylalkyl-or N-[(polycyclyl)alkyl]-N′substituted piperazines
DE19602095A1 (de) 1996-01-22 1997-07-24 Bayer Ag Halogenpyrimidine
ATE236137T1 (de) 1996-02-02 2003-04-15 Merck & Co Inc Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
WO1997029109A1 (fr) 1996-02-07 1997-08-14 Janssen Pharmaceutica N.V. Pyrazolopyrimidines en tant qu'antagonistes du recepteur de crf
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US5776967A (en) 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5830911A (en) 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
TR199900389T2 (xx) 1996-08-28 2000-06-21 Pfizer Inc. �kame edilmi� 6,5-hetero-bisiklik t�revleri.
US6008234A (en) 1996-09-12 1999-12-28 Berlex Laboratories, Inc. Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
ES2188979T3 (es) 1996-09-12 2003-07-01 Schering Ag Derivados de benzamidina sustituidos con derivados de aminoacidos ciclicos e hidroxiacidos ciclicos, y su uso como anti-coagulantes.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
NO980546L (no) 1997-02-11 1998-08-12 Lilly Co Eli Farmas°ytiske midler
AU6279598A (en) 1997-02-18 1998-09-08 Neurocrine Biosciences, Inc. Biazacyclic CRF antagonists
AU751710B2 (en) 1997-04-22 2002-08-22 Neurocrine Biosciences Inc. CRF antagonistic thiophenopyridines
ES2207834T3 (es) 1997-04-22 2004-06-01 Janssen Pharmaceutica N.V. Quino- y quinazolinas antagonistas del crf.
JPH11193277A (ja) 1997-05-14 1999-07-21 Nippon Soda Co Ltd ピリミジン誘導体、その製法および有害生物防除剤
BR9811939A (pt) 1997-08-14 2000-09-05 Bayer Ag Metoximinometiloxadiazinas como pesticidas
DE19737723A1 (de) 1997-08-14 1999-02-18 Bayer Ag Methoximinomethyloxadiazine
NL1010018C2 (nl) 1997-09-09 1999-03-10 Duphar Int Res Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking.
US6861448B2 (en) 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
CA2326383A1 (fr) 1998-04-02 1999-10-14 Neurogen Corporation Derives aminoalkyle substitues de pyrrolo[2,3-b]pyridine et pyrrolo[2,3-d]pyrimidine: modulateurs de recepteurs de crf1
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
AU5777299A (en) 1998-08-21 2000-03-14 Du Pont Pharmaceuticals Company Isoxazolo(4,5-d)pyrimidines as CRF antagonists
JP3635238B2 (ja) 1998-11-10 2005-04-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖの複製を阻害するピリミジン類
US6262088B1 (en) 1998-11-19 2001-07-17 Berlex Laboratories, Inc. Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
DK1133559T3 (da) 1998-11-20 2006-04-10 Arena Pharm Inc Human-G-protein-koblet orphan receptor RUP3
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
EP1140831A1 (fr) 1998-12-17 2001-10-10 American Home Products Corporation Derives d'uree arylpiperidine et aryl-1,2,5,6-tetrahydropyridine presentant une activite de recepteur de 5ht1a
US6239126B1 (en) 1998-12-17 2001-05-29 American Home Products Corporation Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives
EE200100323A (et) 1998-12-18 2002-08-15 Axys Pharmaceuticals, Inc. (Hetero)arüüli - bitsüklilise heteroarüüli derivaadid, nende valmistamine ja nende kasutamine proteaasiinhibiitoritena
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
WO2000055153A1 (fr) 1999-03-17 2000-09-21 Astrazeneca Ab Derives amides
EP1040831A3 (fr) 1999-04-02 2003-05-02 Pfizer Products Inc. Utilisation d'antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
IL145922A0 (en) 1999-04-28 2002-07-25 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
EP1195165A4 (fr) 1999-07-12 2005-08-10 Ono Pharmaceutical Co Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
EP1074549B1 (fr) 1999-08-06 2003-11-19 F. Hoffmann-La Roche Ag Tétrahydro-benzo(d)azépines et leurs utilisations en tant qu'antagonistes du récepteur de glutamate métabotropique
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
KR20020088406A (ko) 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 치료제로서의 피라졸로피리미딘
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
JP2001089452A (ja) 1999-09-22 2001-04-03 Sankyo Co Ltd ピリミジン誘導体
DE60025837T2 (de) 1999-09-24 2006-11-02 Janssen Pharmaceutica N.V. Antivirale feste dispersionen
OA12050A (en) 1999-09-30 2006-05-02 Neurogen Corp Certain alkylene diamine-substituted heterocycles.
YU23602A (sh) 1999-09-30 2004-09-03 Neurogen Corporation Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini
KR20020047198A (ko) 1999-09-30 2002-06-21 해피 페너 ; 해리 에이치. 페너 2세 특정 알킬렌 디아민-치환된피라졸로[1,5-ａ]-1,5-피리미딘 및피라졸로[1,5-ａ]-1,3,5-트리아진
DE19947154A1 (de) 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
CO5271670A1 (es) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
GR990100388A (el) 1999-11-09 2001-07-31 Φαρμακευτικος συνδυασμος αποτελουμενος απο χωριστες δοσολογικες μορφες σε συσκευασια συμμορφωσης (compliance package) ενος αναστολεα της αναγωγασης του υδροξυ-μεθυλο-γλουταρυλο συνενζυμου α (στατινης, statin) και ενος παραγωγου του φιμπρικου οξεος....
WO2001046204A1 (fr) 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Phosphonates aromatiques constituant des inhibiteurs de la phosphatase 1b (ptp-1b) de tyrosine proteique
DE19962936A1 (de) 1999-12-24 2001-06-28 Bayer Ag Neue beta-Aminosäureverbindungen als Integrinantagonisten
AU2152001A (en) 1999-12-30 2001-07-16 H. Lundbeck A/S Phenylpiperazinyl derivatives
MXPA02007047A (es) 2000-01-18 2002-12-13 Pfizer Prod Inc Antagonista del factor liberador de corticotropina.
EP1256582A1 (fr) 2000-02-09 2002-11-13 Hokuriku Seiyaku Co., Ltd. Derives de 1h-imidazopyridine
US6894084B2 (en) 2000-02-15 2005-05-17 Foster-Miller, Inc. No VOC radiation curable resin compositions
US6569879B2 (en) 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
EP1259494A4 (fr) 2000-02-18 2004-09-15 Merck & Co Inc Acides aryloxyacetiques utilises en cas de diabete et de troubles lipidiques
ATE293962T1 (de) 2000-02-25 2005-05-15 Hoffmann La Roche Adenosin-rezeptor modulatoren
CA2405793A1 (fr) 2000-04-12 2001-10-18 Novartis Ag Combinaison de composes organiques
US7034019B2 (en) 2000-05-08 2006-04-25 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines
DE10024319A1 (de) 2000-05-17 2001-11-22 Merck Patent Gmbh Bisacylguanidine
PT1287133E (pt) 2000-05-18 2007-03-30 Bayer Healthcare Ag Regulação do receptor acoplado à proteína g tipo dopamina humano
US6440960B1 (en) 2000-05-18 2002-08-27 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
HUP0302015A2 (hu) 2000-05-25 2003-10-28 F. Hoffmann-La Roche Ag. Helyettesített 1-aminoalkil-laktámok és felhasználásuk muszkarin receptor antagonistaként
US6620821B2 (en) 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
IL153688A0 (en) 2000-06-28 2003-07-06 Teva Pharma Carvedilol
CN1705649A (zh) 2000-06-29 2005-12-07 艾伯特公司 芳基苯基杂环基硫醚衍生物及其作为抑制细胞粘附的抗炎和免疫抑制剂的用途
AR028782A1 (es) 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd Derivados heterociclicos tetrahidropiridino o piperidino
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
KR20030026979A (ko) 2000-07-18 2003-04-03 야마노우치세이야쿠 가부시키가이샤 디시아노피리딘 유도체를 포함하는 의약
JP2004513076A (ja) 2000-07-25 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病治療で有用なｎ−置換インドール類
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
AU2001284417A1 (en) 2000-09-05 2002-03-22 Taisho Pharmaceutical Co. Ltd. Hair growth stimulants
EP1322289B1 (fr) 2000-09-20 2007-07-25 Jagotec AG Procede de sechage par atomisation des compositions de fenofibrate
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
PE20020507A1 (es) 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
AU2002223626A1 (en) 2000-10-20 2002-04-29 Novartis Ag Combinations of a thyromimetic compound and a statin
EP2404603A1 (fr) 2000-10-23 2012-01-11 Glaxosmithkline LLC Nouveaux composés 8H-pyrido[2,3-d]pyrimidin-7-one trisubstituté pour le traitement des maladies faisant intervenir les kinases CSBP/p38.
CA2427610A1 (fr) 2000-10-31 2002-08-08 Merck & Co., Inc. Derives d'acide benzopyranocarboxylique pour traiter le diabete et d'autres troubles lipidiques
DE60126134T2 (de) 2000-11-03 2007-10-18 Neurocrine Biosciences, Inc., San Diego CRF-Rezeptorantagonisten und Verfahren, die damit in Beziehung stehen
US20020058026A1 (en) 2000-11-13 2002-05-16 Milton Hammerly HMG CoA reductase inhibitor medications combined wih CoEnzyme Q-10
WO2002039987A2 (fr) 2000-11-14 2002-05-23 Neurosearch A/S Mise en oeuvre de bloquants des canaux anioniques des parasites de la malaria pour traiter cette maladie
UA77165C2 (en) 2000-11-17 2006-11-15 Lilly Co Eli (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition
US7022725B2 (en) 2000-11-17 2006-04-04 Takeda Pharmaceutical Company Limited Isoxazole derivatives
NZ525700A (en) 2000-11-20 2004-12-24 Biovitrum Ab Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor
ATE348152T1 (de) 2000-12-01 2007-01-15 Astellas Pharma Inc Verfahren zum screening von diabetes- heilverfahren
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US20020107262A1 (en) 2000-12-08 2002-08-08 3M Innovative Properties Company Substituted imidazopyridines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
AU3113902A (en) 2000-12-21 2002-07-01 Bristol Myers Squibb Co Thiazolyl inhibitors of tec family tyrosine kinases
PT1355644E (pt) 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
US6852738B2 (en) 2001-01-30 2005-02-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
EP1383778B1 (fr) 2001-01-30 2009-10-21 University Of Virginia Patent Foundation Agonistes et antagonistes de recepteurs de sphingosine-1-phosphate
EP1383767A1 (fr) 2001-02-08 2004-01-28 Memory Pharmaceutical Corporation Trifluoromethylpurines en tant qu'inhibiteurs de la phosphodiesterase 4
US7091230B2 (en) 2001-02-09 2006-08-15 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
DE10110754A1 (de) 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
WO2002072101A1 (fr) 2001-03-13 2002-09-19 Bristol-Myers Squibb Pharma Company Ligand du recepteur de la corticoliberine, son enantiomere et ses sels pharmaceutiquement acceptables
US7534547B2 (en) 2001-03-29 2009-05-19 Osaka Gas Company Limited Optically active compound and photosensitive resin composition
WO2002081454A1 (fr) 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derives d'acides aryliques et leur utilisation en medecine, procede de preparation de ces derives et compositions pharmaceutiques contenant lesdits derives
EA200301142A1 (ru) 2001-04-20 2004-02-26 Уайт Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
US7179817B2 (en) 2001-05-10 2007-02-20 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DK1397351T3 (da) 2001-06-01 2010-01-18 Hoffmann La Roche Pyrimidin-, triazin- og pyrazinderivater som glutamatreceptorer
WO2002102313A2 (fr) 2001-06-19 2002-12-27 Bristol-Myers Squibb Company Inhibiteurs pyrimidine de la phosphodiesterase (pde) 7
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
CA2451128A1 (fr) 2001-06-26 2003-01-09 Bristol-Myers Squibb Company Inhibiteurs n-heterocycliques d'expression tnf-alpha
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
JPWO2003026661A1 (ja) 2001-09-14 2005-01-06 山之内製薬株式会社 インスリン分泌促進剤及び新規なピリミジン誘導体
AU2002332289B2 (en) 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
JP2005506350A (ja) 2001-10-18 2005-03-03 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン阻害薬としての１，４−二置換ベンゾ−縮合尿素化合物
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
AU2002351752A1 (en) 2001-12-29 2003-07-30 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
WO2003057689A1 (fr) 2002-01-02 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Composes aminopyrimidine, procedes de preparation de ces composes et compositions pharmaceutiques les contenant
US20070225351A1 (en) 2002-01-11 2007-09-27 Lippa Arnold S Methods and compositions for controlling body weight and appetite
JP2005516967A (ja) 2002-01-18 2005-06-09 ザ ジェネティクス カンパニー インコーポレーティッド β−セクレターゼインヒビター
ATE441654T1 (de) 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
GB0201850D0 (en) 2002-01-26 2002-03-13 Astrazeneca Ab Therapeutic treatment
JP2005531506A (ja) 2002-03-01 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体作動薬としてのアミノアルキルホスホネートおよび関連化合物
EP1482896A4 (fr) 2002-03-01 2005-11-23 Merck & Co Inc Aminoalkylphosphonates et composes associes utilises en tant qu'agonistes du recepteur edg
EP1521746B1 (fr) 2002-03-07 2011-04-27 X-Ceptor Therapeutics, Inc. Modulateurs des quinazolinones des recepteurs nucleaires
AU2003214110A1 (en) 2002-03-15 2003-09-29 Ciba Specialty Chemicals Holding Inc. 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
PE20040291A1 (es) 2002-03-22 2004-07-02 Novartis Ag COMBINACION QUE COMPRENDE UN INHIBIDOR DE HMG-CoA-REDUCTASA Y UN POTENCIADOR DE LA SECRECION DE INSULINA Y/O UN SENSIBILIZANTE DE INSULINA
WO2003088962A1 (fr) 2002-04-16 2003-10-30 Merck & Co., Inc. Therapie combinatoire faisant appel a un agoniste de ppar alpha/gamma
EP1499598A1 (fr) 2002-04-18 2005-01-26 Ucb, S.A. Composes chimiques a double activite, procedes de leur preparation et compositions pharmaceutiques
DE10219435A1 (de) 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
WO2003094845A2 (fr) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Ligands du recepteur de la thyroide a base de pyridine
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
EP1511468A1 (fr) 2002-06-10 2005-03-09 Elan Pharma International Limited Preparation de sterols nanoparticulaires et nouvelles combinaisons de sterols
WO2003103640A1 (fr) 2002-06-10 2003-12-18 Elan Pharma International, Ltd Formulations nanoparticulaires comprenant des derives d'un inhibiteur de la hmg coa-reductase (≤statines≥), nouvelles combinaisons associees et production de ces compositions pharmaceutiques
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
CA2488498A1 (fr) 2002-06-10 2003-12-18 Elan Pharma International Limited Formulation de polycosanol nanoparticulaires et nouvelles combinaisons de polycosanol
AU2003243545A1 (en) 2002-06-14 2003-12-31 Amylin Pharmaceuticals, Inc. Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
DE10226943A1 (de) 2002-06-17 2004-01-08 Bayer Ag Phenylaminopyrimidine und ihre Verwendung
JP2005533058A (ja) 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
GB0214254D0 (en) 2002-06-20 2002-07-31 Glaxo Group Ltd Chemical compounds
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0201976D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
DK1531832T3 (da) 2002-06-28 2009-07-27 Glykos Finland Oy Terapeutiske sammensætninger til anvendelse ved profylakse eller behandling af diarré
US20040053842A1 (en) 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
AU2003252478A1 (en) 2002-07-10 2004-02-02 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
JP2006501200A (ja) 2002-07-23 2006-01-12 スミスクライン ビーチャム コーポレーション キナーゼインヒビターとしてのピラゾロピリミジン
AU2003254051A1 (en) 2002-07-23 2004-02-09 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
WO2004009602A1 (fr) 2002-07-23 2004-01-29 Smithkline Beecham Corporation Inhibiteurs de kinase sous forme de pyrazolopyrimidines
EP1527345A2 (fr) 2002-07-29 2005-05-04 Axxima Pharmaceuticals AG Milieu et methode d'enrichissement, de purification ou d'appauvrissement de proteines de liaison a l'atp a partir d'un reservoir de proteines
US7241790B2 (en) 2002-07-30 2007-07-10 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
CA2493913A1 (fr) 2002-07-30 2004-02-05 Merck & Co., Inc. Composes ppar alpha selectifs destines au traitement de la dyslipidemie et autres
AU2003256842B8 (en) 2002-07-30 2009-06-18 Merck Sharp & Dohme Corp. PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
JP2004067575A (ja) 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd 糖尿病治療薬効果促進剤
EP2270006A1 (fr) 2002-08-08 2011-01-05 Amgen, Inc Dérivés de pyridazine en tant que ligands de récepteur vanilloïde
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
JP2006500378A (ja) 2002-08-21 2006-01-05 メルク　エンド　カムパニー　インコーポレーテッド 二元ＰＰＡＲα／γアゴニストとアンギオテンシンＩＩのＩ型受容体アンタゴニストを使用する併用療法
JP4340232B2 (ja) 2002-08-29 2009-10-07 メルク エンド カムパニー インコーポレーテッド 抗糖尿病活性を有するインドール類
NZ538031A (en) 2002-08-29 2007-10-26 Merck & Co Inc Indoles having anti-diabetic activity
US20050191612A1 (en) 2002-09-11 2005-09-01 Takahide Ohishi Method of screening insulin content enhancer
EP1546115A4 (fr) 2002-09-27 2010-08-04 Merck Sharp & Dohme Pyrimidines substituees
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
AU2003282679A1 (en) 2002-10-04 2004-05-04 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
WO2004033710A2 (fr) 2002-10-09 2004-04-22 Genaissance Pharmaceuticals, Inc. Haplotypes du gene itgb3 et effets de doses d'atorvastatine sur le cholesterol hdl
AU2003301302A1 (en) 2002-10-15 2004-05-04 Smithkline Beecham Corporation Pyradazine compounds as gsk-3 inhibitors
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
AU2003285007A1 (en) 2002-10-30 2004-06-07 Merck & Co., Inc. Kinase inhibitors
EP1559422B1 (fr) 2002-11-08 2014-04-30 Takeda Pharmaceutical Company Limited Agent de controle de la fonction recepteur
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US20040110241A1 (en) 2002-12-06 2004-06-10 Segal Mark S. Materials and methods for monitoring vascular endothelial function
JP4516430B2 (ja) 2002-12-20 2010-08-04 メルク・シャープ・エンド・ドーム・コーポレイション １−（アミノ）インダン並びに（１，２−ジヒドロ−３−アミノ）−ベンゾフラン、ベンゾチオフェン及びインドール
WO2004058727A1 (fr) 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation 3,5-dihydro-4-h-imidazol-4-ones substitues utilises dans le traitement de l'obesite
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
AU2003299790A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
GB0230020D0 (en) 2002-12-23 2003-01-29 Syngenta Ltd Fungicides
GB0230021D0 (en) 2002-12-23 2003-01-29 Syngenta Ltd Fungicides
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
ATE359782T1 (de) 2003-01-16 2007-05-15 Sb Pharmco Inc Heteroaryl-substituierte pyrrol(2, 3- b)pyridin- derivate als crf-rezeptor-antagonisten
WO2004066963A2 (fr) 2003-01-17 2004-08-12 Merck & Co., Inc. Derives de n-cyclohexylaminocarbonyl benzenesulfonamide
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
JP4505449B2 (ja) 2003-02-11 2010-07-21 アイアールエム・リミテッド・ライアビリティ・カンパニー 新規二環式化合物および組成物
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
DK1602660T3 (da) 2003-02-18 2011-05-23 Kyorin Seiyaku Kk Aminophosphonsyrederivater, additionssalte deraf og S1P-receptormodulatorer
WO2004076413A2 (fr) 2003-02-24 2004-09-10 Arena Pharmaceuticals, Inc. Derives d'aryle et heteroaryle susbtitues tenant lieu de modulateurs du metabolisme du glucose et prophylaxie et traitement de troubles associes
JP2004269468A (ja) 2003-03-12 2004-09-30 Yamanouchi Pharmaceut Co Ltd ピリミジン誘導体又はその塩
JP2004269469A (ja) 2003-03-12 2004-09-30 Yamanouchi Pharmaceut Co Ltd ピリミジン誘導体又はその塩
CN1795177A (zh) 2003-03-28 2006-06-28 辉瑞产品公司 作为治疗动脉粥样硬化和肥胖症的cetp抑制剂的 1 , 2 , 4 , －取代的1，2，3，4，－四氢－和1，2二氢－喹啉以及1， 2 , 3 ， 4－四氢－喹喔啉衍生物
ATE547395T1 (de) 2003-04-30 2012-03-15 Novartis Pharma Gmbh Aminopropanol-derivate als modulatoren des sphingosin-1-phosphat-rezeptors
ES2392167T3 (es) 2003-04-30 2012-12-05 Novartis Ag Derivados aminopropanol como moduladores del receptor esfingosina-1-fosfato
JP2006525366A (ja) 2003-04-30 2006-11-09 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 複素環式カルボン酸置換基
TWI494102B (zh) 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
DK1475094T3 (da) 2003-05-06 2010-11-22 Univ Palackeho Pyrazolo[4,3-d]pyrimidiner, fremgangsmåde til deres fremstilling samt deres anvendelse
SE0301368D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
US7083933B1 (en) 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
CA2524867A1 (fr) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles servant d'agonistes du recepteur s1p
WO2004104205A2 (fr) 2003-05-16 2004-12-02 Merck & Co., Inc. Preparation enzymatique d'esters d'indole chiraux
AU2004251146A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
CN1787817B (zh) 2003-05-19 2011-09-07 Irm责任有限公司 免疫抑制剂化合物及组合物
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
WO2004113330A1 (fr) 2003-05-19 2004-12-29 Irm Llc Compositions et composes immunosuppresseurs
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
US20060160834A1 (en) 2003-06-06 2006-07-20 Fong Tung M Combination therapy for the treatment of hypertension
AU2003902882A0 (en) 2003-06-10 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Piperidyl derivatives
GB0313612D0 (en) 2003-06-12 2003-07-16 Novartis Ag Organic compounds
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
TWI335328B (en) 2003-07-14 2011-01-01 Arena Pharm Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto
WO2005012221A1 (fr) 2003-08-04 2005-02-10 Ono Pharmaceutical Co., Ltd. Compose d'ether de diphenyle, sa methode de preparation et d'utilisation
TWI378923B (en) 2003-08-15 2012-12-11 Novartis Ag Pyrimidine derivatives
MXPA06002349A (es) 2003-08-28 2006-05-22 Novartis Ag Derivados de aminopropanol.
US7825109B2 (en) 2003-08-29 2010-11-02 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
US20060287528A1 (en) 2003-09-02 2006-12-21 Wenslow Robert M Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2005023762A1 (fr) 2003-09-04 2005-03-17 Abbott Laboratories Derives de pyrrolidine-2-carbonitrile et leur utilisation comme inhibiteurs de la dipeptidyle peptidase-iv (dpp-iv)
US7732442B2 (en) 2003-09-05 2010-06-08 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonist and medical use thereof
PE20050374A1 (es) 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
JP2007505121A (ja) 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
WO2005030751A2 (fr) 2003-09-08 2005-04-07 Takeda Pharmaceutical Company Limited Inhibiteurs de dipeptidyle peptidase
AR046330A1 (es) 2003-09-09 2005-12-07 Japan Tobacco Inc Inhibidor de dipeptidilpeptidasa iv
CA2539707C (fr) 2003-09-23 2011-08-09 Merck & Co., Inc. Inhibiteurs des canaux potassiques a la quinoleine
WO2005030127A2 (fr) 2003-09-23 2005-04-07 Merck & Co., Inc. Nouvelle forme cristalline d'un sel d'acide phosphorique d'un inhibiteur de dipeptidyle peptase-iv
CN1859908A (zh) 2003-10-01 2006-11-08 默克公司 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物
WO2005033099A2 (fr) 2003-10-03 2005-04-14 Glenmark Pharmaceuticals Ltd. Nouveaux inhibiteurs de dipeptidylpeptidase iv, leurs procedes de preparation et compositions les contenant
US20060089335A1 (en) 2003-10-14 2006-04-27 Guosong Liu Compositions and methods for enhancing cognitive function and synaptic plasticity
GB0324236D0 (en) 2003-10-16 2003-11-19 Astrazeneca Ab Chemical compounds
PE20050444A1 (es) 2003-10-31 2005-08-09 Takeda Pharmaceutical Compuestos de piridina como inhibidores de la peptidasa
WO2005041899A2 (fr) 2003-11-03 2005-05-12 University Of Virginia Patent Foundation Agonistes et antagonistes du recepteur de la sphingosine-1-phosphate pouvant etre pris par voie orale
WO2005044780A1 (fr) 2003-11-10 2005-05-19 Kyorin Pharmaceutical Co., Ltd. Derive d'acide aminocarboxylique, son sel d'addition et agent de regulation du recepteur s1p
EP1687004A4 (fr) 2003-11-10 2009-04-08 Synta Pharmaceuticals Corp Composes pyridiniques
EP1689757B1 (fr) 2003-11-12 2014-08-27 Phenomix Corporation Composes heterocycliques d'acide boronique
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005058315A1 (fr) 2003-12-12 2005-06-30 Ribapharm, Inc. Nouveaux composes heterocycliques utilises comme inhibiteurs et presentant une activite anti-hbv
WO2005058849A1 (fr) 2003-12-15 2005-06-30 Glenmark Pharmaceuticals Ltd. Nouveaux inhibiteurs de dipeptidyle peptidase iv, leur procede de preparation et compositions les contenant
AU2004299456B2 (en) 2003-12-17 2010-10-07 Merck Sharp & Dohme Corp. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
JP4766384B2 (ja) 2003-12-19 2011-09-07 小野薬品工業株式会社 リゾホスファチジン酸受容体拮抗作用を有する化合物およびその用途
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
DE10360835A1 (de) 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
BRPI0418149A (pt) 2003-12-24 2007-04-17 Prosidion Ltd derivados heterocìclicos como agonistas do receptor de gprc
US20080227786A1 (en) 2004-01-16 2008-09-18 Ferlita Russell R Novel Crystalline Salts of a Dipeptidyl Peptidase-IV Inhibitor
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2005075426A1 (fr) 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Nouveaux inhibiteurs de dipeptidyle peptidase iv, leur procedes de preparation et compositions en comportant
JP2007522233A (ja) 2004-02-11 2007-08-09 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び治療におけるそれらの使用
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
US7718704B2 (en) 2004-02-24 2010-05-18 Irm Llc Immunosuppressant compounds and compositions
TWI355934B (en) 2004-02-24 2012-01-11 Sankyo Co Pharmaceutical composition for treatment or prophy
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
EP1726585A4 (fr) 2004-03-05 2009-07-15 Banyu Pharma Co Ltd Derive heterocyclique a cinq elements substitues par un diaryle
GB0405289D0 (en) 2004-03-09 2004-04-21 Novartis Ag Organic compounds
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
CA2561632A1 (fr) 2004-04-02 2005-10-20 Merck & Co., Inc. Procede d'hydrogenation asymetrique utile pour la preparation de derives de cycloalcanoindole
AU2005233437A1 (en) 2004-04-12 2005-10-27 Sankyo Company, Limited Thienopyridine derivatives
WO2005117909A2 (fr) 2004-04-23 2005-12-15 Exelixis, Inc. Modulateurs des proteines kinases et leurs methodes d'utilisation
HRP20090093T3 (en) 2004-06-04 2009-03-31 Arena Pharmaceuticals Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005123677A1 (fr) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd Utilisation de derives de 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa[a]pentalene a substitution 4-carbonyle comme agonistes du recepteur couple aux proteines g s1p1/edg1 et agents immunosuppresseurs
JP5315611B2 (ja) 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
ATE502630T1 (de) 2004-07-16 2011-04-15 Kyorin Seiyaku Kk Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
WO2006010379A1 (fr) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Nouveaux derives du thiophene utilises comme agents immunosupresseurs
TW200611687A (en) 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
RU2383536C2 (ru) 2004-08-04 2010-03-10 Тайсо Фармасьютикал Ко., Лтд. Производное триазола
US20060223866A1 (en) 2004-08-13 2006-10-05 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
AU2005272619A1 (en) 2004-08-13 2006-02-23 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (SIP) receptor activity
US20080167321A1 (en) 2004-09-20 2008-07-10 Xenon Pharmaceuticals Inc. Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase
US7250441B2 (en) 2004-09-23 2007-07-31 Wyeth Carbazole and cyclopentaindole derivatives to treat infection with Hepatitis C virus
EP1796669B1 (fr) 2004-10-01 2010-09-22 Merck Sharp & Dohme Corp. Aminopiperidines utilisees comme inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete
CA2583259C (fr) 2004-10-08 2011-08-02 Astellas Pharma Inc. Derive polycyclique aromatique de pyrimidine
CA2583947A1 (fr) 2004-10-12 2006-04-20 Forbes Medi-Tech (Research) Inc. Composes et methodes de traitement de la resistance insulinique et de la myocardiopathie
TW200621257A (en) 2004-10-20 2006-07-01 Astellas Pharma Inc Pyrimidine derivative fused with nonaromatic ring
EP1650186B1 (fr) 2004-10-22 2008-06-04 Bioprojet Nouveaux derivés d'acides dicarboxyliques
JP2008517915A (ja) 2004-10-22 2008-05-29 メルク エンド カムパニー インコーポレーテッド Ｓ１ｐ受容体アゴニストとしての２−（アリール）アザシクリルメチルカルボキシレート、スルホネート、ホスホネート、ホスフィネート及びヘテロ環
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
SG170642A1 (en) 2004-11-03 2011-05-30 Arena Pharm Inc Gpr41 and modulators thereof for the treatment of insulin-related disorders
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
AU2005307718A1 (en) 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids for the treatment of diabetes
US20080051418A1 (en) 2004-11-26 2008-02-28 Tsuyoshi Maekawa Arylalkanoic Acid Derivative
JP2008522977A (ja) 2004-12-06 2008-07-03 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン＝１−リン酸のアリールアミドアナログ
CA2590883A1 (fr) 2004-12-13 2006-06-22 Daiichi Sankyo Company, Limited Composition medicinale pour le traitement du diabete
JP4318087B2 (ja) 2004-12-13 2009-08-19 小野薬品工業株式会社 アミノカルボン酸誘導体およびその医薬用途
WO2006067531A1 (fr) 2004-12-24 2006-06-29 Prosidion Ltd Agonistes du récepteur couplé aux protéines g (gpr116) et leur emploi dans le traitement de l'obésité et du diabète
EP1838706A1 (fr) 2004-12-24 2007-10-03 Prosidion Limited Agonistes du récepteur couplé aux protéines g
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
DOP2006000009A (es) 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
CA2595205A1 (fr) 2005-01-19 2006-07-27 Neurogen Corporation Analogues de piperazinyl-pyridine a substitution heteroaryle
WO2006079406A1 (fr) 2005-01-25 2006-08-03 Merck Patent Gmbh Composes mesogenes, milieu de cristal liquide et affichage a cristaux liquides
EP1685841A1 (fr) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention et traitement de troubles thromboemboliques
MX2007009848A (es) 2005-02-14 2008-03-10 Univ Virginia Agonistas de esfingosina 1-fosfato comprendiendo cicloalcanos y heterociclos de 5 miembros substituidos por grupos amino y fenilo.
BRPI0609668A2 (pt) 2005-03-23 2011-10-18 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
AU2006226018B2 (en) 2005-03-23 2012-07-12 Idorsia Pharmaceuticals Ltd Hydrogenated benzo (C) thiophene derivatives as immunomodulators
KR20080002850A (ko) 2005-03-23 2008-01-04 액테리온 파마슈티칼 리미티드 신규한 티오펜 유도체
JP2008545767A (ja) 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 多環式オキサジアゾールまたはイソキサゾールおよびｓｉｐ受容体リガンドとしてのそれらの使用
US20090105136A1 (en) 2005-06-09 2009-04-23 Jun Suzuki NPY Y2 Agonist for Use as Therapeutic Agent for Disease Accompanied by Diarrhea
TWI418350B (zh) 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途
AU2006260573A1 (en) 2005-06-24 2006-12-28 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives
US20090203676A1 (en) 2005-06-30 2009-08-13 Oscar Barba G-protein Coupled Receptor Agonists
CA2614148A1 (fr) 2005-07-01 2007-01-11 Irm Llc Derives de benzimidazole substitue en pyrimidine en tant qu'inhibiteurs de proteine kinase
US20070060573A1 (en) 2005-08-10 2007-03-15 Lars Wortmann Acyltryptophanols
JP2009506046A (ja) 2005-08-23 2009-02-12 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制剤化合物および組成物
GEP20104966B (en) 2005-09-16 2010-04-26 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200745055A (en) 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
WO2007037196A1 (fr) 2005-09-29 2007-04-05 Yamamoto Chemicals, Inc. Composé indoline et procédé pour le produire
RU2421214C2 (ru) 2005-10-07 2011-06-20 Киорин Фармасьютикал Ко., Лтд. Терапевтическое средство для лечения гепатита и способ лечения гепатита
AU2006317689B2 (en) 2005-11-23 2013-07-25 Epix Delaware, Inc. S1P receptor modulating compounds and use thereof
AR057894A1 (es) 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
EA019879B1 (ru) 2005-12-29 2014-07-30 Лексикон Фармасьютикалз, Инк. Полициклические производные аминокислот, содержащая их фармацевтическая композиция и способ лечения, использующий эти производные
TWI404706B (zh) 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
TW200736234A (en) 2006-01-17 2007-10-01 Astrazeneca Ab Chemical compounds
PL1973884T3 (pl) 2006-01-19 2017-05-31 Orchid Pharma Limited Nowe związki heterocykliczne
KR20080092385A (ko) 2006-01-24 2008-10-15 액테리온 파마슈티칼 리미티드 신규한 피리딘 유도체
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
AU2007212193A1 (en) 2006-02-09 2007-08-16 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
TW200806611A (en) 2006-02-09 2008-02-01 Daiichi Seiyaku Co Novel amidopropionic acid derivatives and medicine containing the same
US20070191371A1 (en) 2006-02-14 2007-08-16 Kalypsys, Inc. Heterocyclic modulators of ppar
CA2642668C (fr) 2006-02-15 2013-01-08 Allergan, Inc. Composes d'amides et esters d'acide indole-3-carboxylique comportant des groupes phenyles ayant une activite biologique antagoniste du recepteur sphingosine-1-phosphate (s1p)
CN101460458A (zh) 2006-02-15 2009-06-17 阿勒根公司 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物
BRPI0707957A2 (pt) 2006-02-21 2011-05-17 Univ Virginia Patent Found composto, e, método para prevenção ou tratamento de uma condição ou sintoma patológico em um mamìfero
US7649098B2 (en) 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
CA2646430A1 (fr) 2006-03-14 2007-09-20 Amgen Inc. Derives bicycliques de l'acide carboxylique utiles dans le traitement de troubles metaboliques
US7790707B2 (en) 2006-03-21 2010-09-07 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
JP2007262009A (ja) 2006-03-29 2007-10-11 Dai Ichi Seiyaku Co Ltd ヘテロアリール低級カルボン酸誘導体
MX2008012738A (es) 2006-04-03 2009-02-06 Astellas Pharma Inc Heterocompuesto.
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
ES2354390T3 (es) 2006-04-11 2011-03-14 Arena Pharmaceuticals, Inc. Procedimientos de uso del receptor gpr119 para identificar compuestos útiles para aumentar la masa ósea en un individuo.
GB0607389D0 (en) 2006-04-12 2006-05-24 Novartis Ag Organic compounds
MX2008013990A (es) 2006-05-09 2009-01-29 Pfizer Prod Inc Derivados de cicloalquilamino acidos.
EP2017263A4 (fr) 2006-05-09 2011-11-30 Daiichi Sankyo Co Ltd Derive acide carboxylique inferieur d'heteroarylamide
WO2007129473A1 (fr) 2006-05-09 2007-11-15 Daiichi Sankyo Company, Limited Dérivé arylique bicyclique
TW200811147A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811140A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
JP2009543805A (ja) 2006-07-13 2009-12-10 スミスクライン ビーチャム コーポレーション インドリン誘導体及びｇｐｒ１１９作動物質
AR062156A1 (es) 2006-08-01 2008-10-22 Praecis Pharm Inc Compuestos agonistas y selectivos del receptor s1p-1
US20080070866A1 (en) 2006-08-01 2008-03-20 Praecis Pharmaceuticals Incorporated Chemical compounds
EP2099768A2 (fr) 2006-08-04 2009-09-16 Praecis Pharmaceuticals Incorporated Agonistes du recepteur de sphingosine-1-phosphate
US8232319B2 (en) 2006-08-08 2012-07-31 Kyorin Pharmaceutical Co., Ltd. Amino phosphate derivative and S1P receptor modulator having same as an active ingredient
EP2054377A1 (fr) 2006-08-24 2009-05-06 Praecis Pharmaceuticals Incorporated Composés chimiques
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
CA2661371A1 (fr) 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Composes de pyrimidine permettant de traiter des troubles lies a gpr119
AR061841A1 (es) 2006-09-07 2008-09-24 Actelion Pharmaceuticals Ltd Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
CA2662852A1 (fr) 2006-09-07 2008-03-13 Allergan, Inc. Composes heteroaromatiques presentant une activite biologique agoniste et/ou antagoniste sur le recepteur sphingosine-1-phosphate (s1p)
CL2007002593A1 (es) 2006-09-07 2008-06-13 Actelion Pharmaceuticals Ltd Compuestos derivados de 4-heteroaril-piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo de organos transplantados, sindromes autoinmunes y cancer.
CA2662091A1 (fr) 2006-09-08 2008-03-13 Novartis Ag Derives du n-biaryl (hetero) arylsulphonamide utilisables pour traiter des maladies induites par des interactions avec les lymphocytes
EP2069318B1 (fr) 2006-09-21 2012-09-12 Actelion Pharmaceuticals Ltd. Dérivés phényliques et utilisation de ceux-ci en tant qu'immunomodulateurs
CN101657471B (zh) 2006-12-06 2013-07-03 史密丝克莱恩比彻姆公司 二环化合物及其作为抗糖尿病药的用途
US8399485B2 (en) 2006-12-14 2013-03-19 Merck Sharp & Dohme Corp. Acyl bipiperidinyl compounds useful as GPR 119 agonists
CN101562977A (zh) 2006-12-15 2009-10-21 艾博特公司 新的二唑化合物
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
CA2672727A1 (fr) 2006-12-21 2008-07-03 Abbott Laboratories Composes d'agonistes et d'antagonistes des recepteurs de sphingosine-1-phosphate
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
JP2010515750A (ja) 2007-01-11 2010-05-13 アラーガン インコーポレイテッド スフィンゴシン−１−ホスフェート（ｓ１ｐ）受容体アンタゴニスト生物活性を有する６−置換インドール−３−カルボン酸アミド化合物
WO2008091967A1 (fr) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Composés chimiques
WO2008097819A2 (fr) 2007-02-05 2008-08-14 Smithkline Beecham Corporation Composés chimiques
JP2010521450A (ja) 2007-03-16 2010-06-24 アクテリオン ファーマシューティカルズ リミテッド Ｓ１ｐ１／ｅｄｇ１受容体アゴニストとしてのアミノ−ピリジン誘導体
JP5191497B2 (ja) 2007-03-21 2013-05-08 エピックス ファーマシューティカルズ，インコーポレイテッド Ｓ１ｐ受容体調節化合物およびその使用
WO2008128832A1 (fr) 2007-04-18 2008-10-30 Nicox S.A. Nitrodérivés non peptidiques d'inhibiteurs de la rénine destinés au traitement de maladies cardiovasculaires, rénales et chroniques du foie, des inflammations et du syndrome métabolique
CL2008001099A1 (es) 2007-04-19 2008-10-24 Glaxo Group Ltd Compuestos derivados de indazol; y su uso para tratar enfermedades mediadas por los receptores s1p1, tales como esclerosis multiple, enfermedad autoinmune, trastornos inflamatorios, diabetes, entre otras.
ES2388967T3 (es) 2007-05-04 2012-10-22 Bristol-Myers Squibb Company Agonistas [6,6]- y [6,7]-bicíclicos del receptor GPR119 acoplado a la proteína G
EP2014653A1 (fr) 2007-06-15 2009-01-14 Bioprojet Nouveaux dérivés d'acide dicarboxylique comme agonistes du recepteur S1P1
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
WO2009019506A1 (fr) 2007-08-03 2009-02-12 Astrazeneca Ab Sulfonamides hétérocycliques ayant une activité antagoniste de edg-1
BRPI0814975A2 (pt) 2007-08-08 2015-02-03 Merck Serono Sa Derivados de 6-amino-pirimidina-4-carboxamida e compostos relacionados que se ligam ao receptor de 1-fosfato de esfingosina (s1p) para o tratamento de esclerose múltipla
CA2697551C (fr) 2007-09-20 2013-03-12 Irm Llc Composes et compositions en tant que modulateurs de l'activite de gpr119
UY31468A1 (es) 2007-11-15 2009-07-17 Derivados bis-(sulfonilamino) en terapia 065
US8637704B2 (en) 2007-11-28 2014-01-28 Synta Pharmaceuticals Corp. Polymorphs of N-malonyl-bis(N′-methyl-N′-thiobenzoylhydrazide)
AU2008338965A1 (en) 2007-12-18 2009-06-25 Arena Pharmaceuticals, Inc. Tetrahydrocyclopenta[b]indol-3-yl carboxylic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
CA2711887A1 (fr) 2008-01-25 2009-07-30 Arena Pharmaceuticals, Inc. Derives carboxyliques dihydro-1h-pyrrolo[1,2-a]indol-1-yle agissant comme des agonistes de s1p1
AR070398A1 (es) 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
EP2258040A2 (fr) 2008-02-28 2010-12-08 Solar Roofing Systems, Inc. Tuile photovoltaïque avec matériau anti-incendie
WO2009115954A1 (fr) 2008-03-17 2009-09-24 Actelion Pharmaceuticals Ltd Régime de dosage pour un agoniste sélectif du récepteur s1p<sb>1</sb>
JP2011516557A (ja) 2008-04-07 2011-05-26 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性のモジュレーターとしての化合物および組成物
WO2009125434A2 (fr) 2008-04-07 2009-10-15 Cadila Healthcare Limited Dérivés d’oxime
EP2146210A1 (fr) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Procédés d'utilisation du récepteur couplé aux protéines A G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement d'états modulés par PYY
HUE025984T2 (hu) 2008-05-14 2016-05-30 Scripps Research Inst Szfingozin foszfát receptor új modulátorai
WO2009151621A1 (fr) 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Dérivés de l’acide (1, 2, 4-oxadiazol-3-yl)indolin-1-yl carboxylique substitué utiles comme agonistes de s1p1
WO2009151626A1 (fr) 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Dérivés de l’acide (1, 2, 4-oxadiazol-3-yl)indolin-1-yl carboxylique substitué pouvant être utilisés comme agonistes de s1p1
HRP20161133T1 (hr) 2008-07-23 2016-12-02 Arena Pharmaceuticals, Inc. DERIVATI SUSPSTITUIRANE 1,2,3,4-TETRAHIDROCIKLOPENTA[b]INDOL-3-IL-OCTENE KISELINE KORISNI U LIJEČENJU AUTOIMUNIH I UPALNIH POREMEĆAJA
CN105816453B (zh) 2008-08-27 2021-03-05 艾尼纳制药公司 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物
WO2010072703A1 (fr) 2008-12-22 2010-07-01 Novartis Ag Régime posologique d'un agoniste du récepteur s1p
PL2379067T3 (pl) 2008-12-22 2016-02-29 Novartis Ag Schemat dawkowania fingolimodu w leczeniu stwardnienia rozsianego
WO2010075271A1 (fr) 2008-12-23 2010-07-01 Schering Corporation Dérivés d'hétérocycles bicycliques et leurs procédés d'utilisation
WO2010075273A1 (fr) 2008-12-23 2010-07-01 Schering Corporation Dérivés d'hétérocycles bicycliques et leurs procédés d'utilisation
WO2010074271A1 (fr) 2008-12-26 2010-07-01 武田薬品工業株式会社 Agent thérapeutique pour le diabète
WO2010084944A1 (fr) 2009-01-22 2010-07-29 田辺三菱製薬株式会社 NOUVEAU COMPOSÉ PYRROLO[2,3-d] PYRIMIDINE
AU2010213794A1 (en) 2009-02-10 2011-09-01 Abbott Laboratories Agonists and antagonists of the S1P5 receptor, and methods of uses thereof
WO2011005290A1 (fr) 2009-06-23 2011-01-13 Arena Pharmaceuticals, Inc. Dérivés d'oxadiazole disubstitués utiles dans le traitement de troubles auto-immuns et inflammatoires
WO2011005295A1 (fr) 2009-06-24 2011-01-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur sphingosine-1-phosphate (s1p) utiles pour le traitement de troubles associés à ceux-ci
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
AR077638A1 (es) 2009-07-15 2011-09-14 Lilly Co Eli Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad
WO2011030139A1 (fr) 2009-09-11 2011-03-17 Astrazeneca Ab Derives de 4-(pyrimidin-2-yl)-piperazine et de 4-(pyrimidin-2-yl)-piperidine utilises en tant que modulateurs du gpr119
CN102686571B (zh) 2009-10-29 2015-11-25 百时美施贵宝公司 三环杂环化合物
US8299059B2 (en) 2009-10-30 2012-10-30 Eli Lilly And Company Crystalline compound and a process for its preparation
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
MTP4285B (en) 2009-12-30 2011-07-04 Medichem Sa A 1-(1h-1,2,3-triazol-1-yl)butan-2-ol derivative for pharmaceutical use, and the use of a 1-(1h-1, 2, 4- triazol-1yl) butan-2-ol derivative with substially undefined crystal shap for preparing said 1-(1h-1, 2, 4-triazol-1-yl0 butan-2-ol derivative
CA2786994C (fr) 2010-01-27 2018-01-16 Arena Pharmaceuticals, Inc. Procedes de preparation d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta]indol-3-yl) acetique et de ses sels
CN105503882B (zh) 2010-03-03 2019-07-05 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
MX2012011631A (es) 2010-04-06 2013-01-18 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
EP2598126A2 (fr) 2010-07-30 2013-06-05 Saint Louis University Méthodes de traitement de la douleur
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
PT2672823T (pt) 2011-02-07 2016-11-21 Biogen Ma Inc Agentes que modulam s1p
WO2012135570A1 (fr) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles qui lui sont associés
WO2012145361A1 (fr) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (fr) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
WO2013055910A1 (fr) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
US20160038506A1 (en) 2012-02-14 2016-02-11 Repros Therapeutics Inc. Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof
US8962888B2 (en) 2012-12-03 2015-02-24 Physical Sciences, Inc. Forming spherical crystal habit
JP5589110B1 (ja) 2013-03-08 2014-09-10 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
EP2981819A1 (fr) 2013-04-04 2016-02-10 Novartis AG Identification de la réponse d'un patient à une administration d'un modulateur de récepteur de s1p
KR102337598B1 (ko) 2013-05-03 2021-12-10 신닥스 파마슈티컬스, 인크. 암 치료 방법
WO2016100310A1 (fr) 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Formulations de 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-méthylcyclohexylamino)-pyrimidine-5-carboxamide
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
WO2016164180A1 (fr) 2015-04-06 2016-10-13 Auspex Pharmaceuticals, Inc. Oxadiazoles substitués par du deutérium
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
JP2020507610A (ja) * 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ， インコーポレイテッド 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
WO2020072824A1 (fr) 2018-10-03 2020-04-09 Arena Pharmaceuticals, Inc. Méthodes pour le traitement des troubles de la sclérodermie
AU2019387212A1 (en) 2018-11-30 2021-06-24 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
AU2020206700A1 (en) 2019-01-08 2021-07-15 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P

Also Published As

Publication number Publication date
JP2021527050A (ja) 2021-10-11
MX2020013157A (es) 2021-04-29
AU2019280822A8 (en) 2021-01-28
US20210228545A1 (en) 2021-07-29
KR20210029190A (ko) 2021-03-15
US12156866B2 (en) 2024-12-03
US20250090497A1 (en) 2025-03-20
IL279180A (en) 2021-01-31
CA3102136A1 (fr) 2019-12-12
EP3801459A1 (fr) 2021-04-14
EP3801459B1 (fr) 2024-08-07
KR102859841B1 (ko) 2025-09-12
ES2987794T3 (es) 2024-11-18
WO2019236757A1 (fr) 2019-12-12
JP7397011B2 (ja) 2023-12-12
BR112020024762A2 (pt) 2021-03-23
AU2019280822A1 (en) 2021-01-07
CN112601516A (zh) 2021-04-02

Similar Documents

Publication Publication Date Title
MA51673A (fr) Composés destinés au traitement de troubles dépendant de la kinase
EP3411380A4 (fr) Composés destinés au traitement de troubles ou de maladies oculaires
EP3813808A4 (fr) Méthodes de traitement de la toxicomanie
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
EP3448398A4 (fr) Compositions et méthodes pour le traitement de troubles cutanés
SI3716992T1 (sl) Uporaba antagonistov VEGF za zdravljenje angiogenih očesnih motenj
EP3340982A4 (fr) Composés pour le traitement de troubles immunitaires et inflammatoires
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
MA47212A (fr) Méthodes de traitement de troubles neurologiques
EP3630102A4 (fr) Formulations pour le traitement d&#39;un trouble de stress post-traumatique
MA42953A (fr) Composés et compositions pour le traitement de troubles oculaires
EP3621434A4 (fr) Méthodes de traitement de troubles neuropsychiatriques
MA53329A (fr) Méthodes de traitement de l&#39;épilepsie
EP3731859A4 (fr) Méthodes de traitement de troubles associés à castor
MA47207A (fr) Composés utiles pour le traitement de troubles du tractus digestif
EP3352755A4 (fr) Nouveaux composés, compositions et méthodes pour le traitement de troubles cutanés
EP3402477A4 (fr) Méthodes pour le traitement de troubles associés à des cellules suppressives dérivées de cellules myéloïdes
EP3826650A4 (fr) Méthodes de traitement de troubles neurologiques
EP3773491A4 (fr) Méthodes de traitement de troubles associés à l&#39;apoe4/4
IL279180A (en) Methods of treating conditions related to the S1P1 receptor
MA49140A (fr) Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques
EP3442554A4 (fr) Compositions et méthodes pour le traitement de troubles associés à la néovascularisation
MA51738A (fr) Composés pour le traitement de la douleur
EP3377105A4 (fr) Compositions pour le traitement de troubles de la calcification ectopique, et méthodes les utilisant
MA46099A (fr) Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial